本研究旨在应用网络药理学探索如仙舒喉方对三阴性乳腺癌（TNBC）的分子机制。通过中药系统药理学数据库获取了该方的活性成分和靶点。使用Gencards数据库、在线Mendelian继承人数据库、治疗靶点数据库和DRUGBANK数据库搜索TNBC相关靶点。通过有效成分作用靶点和疾病靶点的交集，筛选出如仙舒喉方对TNBC的潜在靶点。建立并分析了一种草药-活性成分-靶点网络，用于研究关键成分。构建了蛋白质相互作用网络，用于研究关键靶点。此外，进行了基因本体分析和Kyoto基因及基因组通路富集分析。最后，通过分子对接评估了关键成分与关键基因之间的关系。如仙舒喉方用于治疗TNBC的关键成分可能是槲皮素、黄酮素和山奈酚，而关键治疗靶点可能是蛋白激酶B、白细胞介素-6、细胞肿瘤抗原p53和血管内皮生长因子A。相关信号通路主要涉及肿瘤、凋亡和病毒感染，并且其中PI3K-Akt信号通路与TNBC密切相关。分子对接显示关键成分与关键靶点有很高的结合活性。如仙舒喉方对TNBC的分子机制可能涉及多成分、多靶点和多通路。版权所有© 2023作者。由Wolters Kluwer Health，Inc.发表。

We aimed to explore the molecular mechanism of Ruxian Shuhou prescription in the treatment of triple-negative breast cancer (TNBC) by using network pharmacology. The active components and targets of the prescription were obtained by Traditional Chinese medicine systems pharmacology database. Gencards database, online mendelian inheritance in man database, therapeutic target database, and DRUGBANK database were used to search for the TNBC-related targets. The potential targets of Ruxian Shuhou prescription for TNBC were screened out by the intersection of effective ingredient action targets and disease targets. A herb-active ingredient-target network was constructed and analyzed for key ingredients. A protein-protein interaction network was constructed for studying key targets. Furthermore, gene ontology analysis and Kyoto encyclopedia of genes and genomes pathway enrichment analysis were carried out. Finally, the relationship between key ingredients and key genes was evaluated by molecular docking. The key ingredients of Ruxian Shuhou prescription for the treatment of TNBC may be Quercetin, Luteolin and Kaempferol, while the key therapeutic targets may be protein kinase B, interleukin-6, cellular tumor antigen p53, and vascular endothelial growth factor A. The related signaling pathways were mainly involved in tumor, apoptosis and virus infection, among which the PI3K-Akt signaling pathway was the most closely related to TNBC. Molecular docking showed that the key ingredients had high binding activity with the key targets. The molecular mechanisms of Ruxian Shuhou prescription for TNBC are likely to involve multi-ingredient, multi-target and multi-pathway.Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.